

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human CD39/ENTPD1 in direct ELISAs and Western blots. In direct ELISAs, no cross-reactivity with recombinant mouse CD39 or recombinant human CD39L2, 3, or 4 is observed.
Source	Monoclonal Mouse IgG _{2B} Clone # 498409
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	Chinese hamster ovary cell line CHO-derived recombinant human CD39 Thr38-Val478 Accession # P49961
Conjugate	Alexa Fluor 594 Excitation Wavelength: 590 nm Emission Wavelength: 617 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Western Blot Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

Ectonucleoside triphosphate diphosphohydrolase-1 (ENTPD1), also called NTPDase-1 and designated CD39, is an integral membrane protein with an extracellular active site. ENTPD1 was originally described as a B lymphocyte cell surface marker (2), but it is also present on the surface of natural killer cells, T cells, and some endothelial cells (3). ENTPD1 hydrolyzes the β- and γ phosphate residues of nucleotides, preferring ATP as the substrate. Through its hydrolysis of extracellular nucleotides, ENTPD1 plays a role in the regulation of purinergic signaling (4). ENTPD1 is involved in the processes of thromboregulation and vascular inflammation (5). The administration of soluble ENTPD1 may have therapeutic applications for the treatment of some vascular and transplantation-associated diseases (6). The amino acid sequence of human ENTPD1 shares 77% and 75% identity with that of mouse and rat ENTPD1, respectively.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.